All Journals > Clinical Infectious Diseases > 1 February 2004 > Clinical Features of hVISA Bacteremia

Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

CID LISTED AMONG
“MOST INFLUENTIAL”

Clinical Infectious Diseases has been named as one of the "100 Most Influential Journals in Biology and Medicine" of the past 100 years by the Special Libraries Association. The list was compiled by the 680-plus members of SLA’s Biomedical and Life Sciences Division.

See the full list here.

Source: The DBIO 100, the 100 Most Influential Journals in Biology & Medicine over the last 100 Years

In the News

Featured in MSNBC
"Germs and flu are up; infection control is down" June 9, 2009
Trends in the Incidence of Methicillin‐Resistant Staphylococcus aureus Infection in Children’s Hospitals in the United States
Jeffrey S. Gerber, Susan E. Coffin, Sarah A. Smathers, and Theoklis E. Zaoutis
Just this week, researchers reported that the incidence of MRSA infections among children admitted to pediatric hospitals in the United States more than tripled between 2002 and 2007. Researchers at the Children’s Hospital of Philadelphia and the University of Pennsylvania found cases of MRSA jumped from 6.7 per 1,000 admissions in 2002 to 21.1 cases per 1,000 admissions in 2007, according to a study released online Monday in the journal Clinical Infectious Diseases.

Featured in Toronto Star
"Pigs, viruses and politics" May 2, 2009
Are Swine Workers in the United States at Increased Risk of Infection with Zoonotic Influenza Virus?
Kendall P. Myers, Christopher W. Olsen, Sharon F. Setterquist, Ana W. Capuano, Kelley J. Donham, Eileen L. Thacker, James A. Merchant, and Gregory C. Gray
Another study, this one published in the U.S. journal Clinical Infectious Diseases in 2006, found that workers in meat-processing plants have a greater likelihood of being infected by some version of the H1N1 flu virus than the general population (the odds of pig farmers getting the disease are significantly greater again).

Featured in Philadelphia Inquirer
"A shot in the arm for vaccines" April 19, 2009
Vaccines: Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection
Lisa A. Jackson and Edward N. Janoff
Every year, an estimated 915,000 people 65 and older get pneumonia, and 40 percent of them end up in hospitals, according to a 2004 paper in the journal Clinical Infectious Diseases. Pneumonia often kills older people, said Richard Stefanacci, a geriatrician at the University of the Sciences in Philadelphia.

1 February 2004

Volume 38, Number 3
Clinical Infectious Diseases 2004;38:448–451
© 2004 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2004/3803-0025$15.00
DOI: 10.1086/381093
BRIEF REPORT

Clinical Features Associated with Bacteremia Due to Heterogeneous Vancomycin‐Intermediate Staphylococcus aureus

Patrick G. P. Charles,1

Peter B. Ward,2

Paul D. R. Johnson,1

Benjamin P. Howden,1,2 and

M. Lindsay Grayson1

Departments of 1Infectious Diseases and 2Microbiology, Austin Health, Heidelberg, Victoria, Australia

We assessed all episodes of methicillin‐resistant Staphylococcus aureus (MRSA) bacteremia at our hospital during a 12‐month period ( ) and compared those due to heterogeneous vancomycin‐intermediate S. aureus (hVISA; n=5, 9.4%) with those due to vancomycin‐susceptible MRSA ( ). Patients with hVISA bacteremia were more likely to have high bacterial load infections ( ), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; 1), and initially low serum vancomycin levels ( ). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment.

Received 10 June 2003; accepted 7 October 2003; electronically published 12 January 2004.

Reprints and correspondence: Dr. Patrick Charles, Dept. of Infectious Diseases, Austin Health, Studley Rd., Heidelberg, Victoria, 3084, Australia ().

Cited by

R. K. C. Fong, J. Low, T. H. Koh, A. Kurup. (2009) Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. European Journal of Clinical Microbiology & Infectious Diseases
Online publication date: 22-May-2009.
CrossRef
G. Ralph Corey. (2009) Staphylococcus aureus Bloodstream Infections: Definitions and Treatment. Clinical Infectious Diseases 48:s4, S254-S259
Online publication date: 15-May-2009.
Abstract-Full Text-PDF Version (257 kB)
Yasmin Maor, Michal Hagin, Natasha Belausov, Nathan Keller, Debbi Ben‐David, and Galia Rahav. (2009) Clinical Features of Heteroresistant Vancomycin‐Intermediate Staphylococcus aureus Bacteremia versus Those of Methicillin‐Resistant S. aureus Bacteremia. The Journal of Infectious Diseases 199:5, 619-624
Online publication date: 1-Mar-2009.
Abstract-Full Text-PDF Version (154 kB)
Stan Deresinski. (2009) Vancomycin Heteroresistance and Methicillin‐Resistant Staphylococcus aureus. The Journal of Infectious Diseases 199:5, 605-609
Online publication date: 1-Mar-2009.
Citation-Full Text-PDF Version (62 kB)
J. Garau, E. Bouza, J. Chastre, F. Gudiol, S. Harbarth. (2009) Management of methicillin-resistant Staphylococcus aureus infections. Clinical Microbiology and Infection 15:2, 125-136
Online publication date: 1-Mar-2009.
CrossRef
Anton Y. Peleg, Divya Monga, Satish Pillai, Eleftherios Mylonakis, Robert C. Moellering, Jr., and George M. Eliopoulos. (2009) Reduced Susceptibility to Vancomycin Influences Pathogenicity in Staphylococcus aureus Infection. The Journal of Infectious Diseases 199:4, 532-536
Online publication date: 15-Feb-2009.
Abstract-Full Text-PDF Version (1910 kB)
S. N. Leonard, K. L. Rossi, K. L. Newton, M. J. Rybak. (2009) Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. Journal of Antimicrobial Chemotherapy 63:3, 489-492
Online publication date: 15-Feb-2009.
CrossRef
Yan Q. Xiong, Vance G. Fowler, Jr., Michael R. Yeaman, Francoise Perdreau‐Remington, Barry N. Kreiswirth, and Arnold S. Bayer. (2009) Phenotypic and Genotypic Characteristics of Persistent Methicillin‐Resistant Staphylococcus aureus Bacteremia In Vitro and in an Experimental Endocarditis Model. The Journal of Infectious Diseases 199:2, 201-208
Online publication date: 15-Jan-2009.
Abstract-Full Text-PDF Version (236 kB)
Peter K Linden. (2009) Vancomycin resistance: are there better glycopeptides coming?. Expert Review of Anti-infective Therapy 6:6, 917-928
Online publication date: 1-Jan-2009.
CrossRef
A. P. MacGowan, . (2008) Clinical implications of antimicrobial resistance for therapy. Journal of Antimicrobial Chemotherapy 62:Supplement 2, ii105-ii114
Online publication date: 1-Dec-2008.
CrossRef
S. N. Leonard, M. J. Rybak. (2008) Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Journal of Antimicrobial Chemotherapy 63:1, 155-160
Online publication date: 18-Nov-2008.
CrossRef
Marin H. Kollef, Lena M. Napolitano, Joseph S. Solomkin, Richard G. Wunderink, In‐Gyu Bae, Vance G. Fowler, Robert A. Balk, Dennis L. Stevens, James J. Rahal, Andrew F. Shorr, Peter K. Linden, and Scott T. Micek. (2008) Health Care–Associated Infection (HAI): A Critical Appraisal of the Emerging Threat—Proceedings of the HAI Summit. Clinical Infectious Diseases 47:s2, S55-S99
Online publication date: 1-Oct-2008.
Abstract-Full Text-PDF Version (860 kB)
George Sakoulas and Robert C. Moellering, Jr.. (2008) Increasing Antibiotic Resistance among Methicillin‐Resistant Staphylococcus aureus Strains. Clinical Infectious Diseases 46:s5, S360-S367
Online publication date: 1-Jun-2008.
Abstract-Full Text-PDF Version (410 kB)
Sara E. Cosgrove and Vance G. Fowler, Jr.. (2008) Management of Methicillin‐Resistant Staphylococcus aureus Bacteremia. Clinical Infectious Diseases 46:s5, S386-S393
Online publication date: 1-Jun-2008.
Abstract-Full Text-PDF Version (336 kB)
Steven N Leonard, Michael J Rybak. (2008) Telavancin: An Antimicrobial with a Multifunctional Mechanism of Action for the Treatment of Serious Gram-Positive Infections. Pharmacotherapy 28:4, 458-468
Online publication date: 1-May-2008.
CrossRef
Marin H. Kollef. (2007) Limitations of Vancomycin in the Management of Resistant Staphylococcal Infections. Clinical Infectious Diseases 45:s3, S191-S195
Online publication date: 15-Sep-2007.
Abstract-Full Text-PDF Version (252 kB)
Thomas P Lodise, Peggy S McKinnon. (2007) Burden of Methicillin-Resistant Staphylococcus aureus: Focus on Clinical and Economic Outcomes. Pharmacotherapy 27:7, 1001-1012
Online publication date: 1-Aug-2007.
CrossRef
Scott D Pope, Andrew M Roecker. (2007) Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections. Expert Opinion on Pharmacotherapy 8:9, 1245-1261
Online publication date: 1-Jul-2007.
CrossRef
Stan Deresinski. (2007) Vancomycin: does it still have a role as an antistaphylococcal agent?. Expert Review of Anti-infective Therapy 5:3, 393-401
Online publication date: 1-Jul-2007.
CrossRef
M. M. Mwangi, S. W. Wu, Y. Zhou, K. Sieradzki, H. de Lencastre, P. Richardson, D. Bruce, E. Rubin, E. Myers, E. D. Siggia, A. Tomasz. (2007) Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proceedings of the National Academy of Sciences 104:22, 9451-9456
Online publication date: 29-Jun-2007.
CrossRef
John F. Mohr and Barbara E. Murray. (2007) Point: Vancomycin Is Not Obsolete for the Treatment of Infection Caused by Methicillin‐Resistant Staphylococcus aureus. Clinical Infectious Diseases 44:12, 1536-1542
Online publication date: 15-Jun-2007.
Abstract-Full Text-PDF Version (375 kB)
Stan Deresinski. (2007) Counterpoint: Vancomycin and Staphylococcus aureus—An Antibiotic Enters Obsolescence. Clinical Infectious Diseases 44:12, 1543-1548
Online publication date: 15-Jun-2007.
Abstract-Full Text-PDF Version (227 kB)
Michael Vercillo, Michael J Patzakis, Paul Holtom, Charalampos G Zalavras. (2007) Linezolid in the Treatment of Implant-related Chronic Osteomyelitis. Clinical Orthopaedics and Related Research PAP,
Online publication date: 1-Jun-2007.
CrossRef
Erika L. Bessette, John W. Ahern, W. Kemper Alston. (2007) Risk Factors for Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia Despite Treatment With Vancomycin. Infectious Diseases in Clinical Practice 15:3, 174-177
Online publication date: 1-Jun-2007.
CrossRef
J. Gómez, E. García-Vázquez, R. Baños, M. Canteras, J. Ruiz, V. Baños, J. A. Herrero, M. Valdés. (2007) Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy. European Journal of Clinical Microbiology & Infectious Diseases 26:4, 239-245
Online publication date: 4-May-2007.
CrossRef
Fred C. Tenover and Robert C. Moellering, Jr.. (2007) The Rationale for Revising the Clinical and Laboratory Standards Institute Vancomycin Minimal Inhibitory Concentration Interpretive Criteria for Staphylococcus aureus. Clinical Infectious Diseases 44:9, 1208-1215
Online publication date: 1-May-2007.
Abstract-Full Text-PDF Version (415 kB)
Emma J Bishop, Benjamin P Howden. (2007) Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions. Expert Opinion on Emerging Drugs 12:1, 1-22
Online publication date: 1-Apr-2007.
CrossRef
Richard H Drew. (2007) Emerging Options for Treatment of Invasive, Multidrug-Resistant Staphylococcus aureus Infections. Pharmacotherapy 27:2, 227-249
Online publication date: 1-Mar-2007.
CrossRef
A. W. Karchmer. (2007) From theory to practice: resistance in Staphylococcus aureus and new treatments. Clinical Microbiology and Infection 12:s8, 15-21
Online publication date: 1-Jan-2007.
CrossRef
Marci Drees, Helen Boucher. (2007) New agents for Staphylococcus aureus endocarditis. Current Opinion in Infectious Diseases 19:6, 544???550
Online publication date: 1-Jan-2007.
CrossRef
Susan J. Rehm. (2006) Treatment of Serious Infections Caused by Methicillin-resistant Staphylococcus aureus. Infectious Diseases in Clinical Practice 14:5, 251-253
Online publication date: 1-Oct-2006.
CrossRef
Jeffrey C. Hageman, Laura A. Liedtke, Rebecca H. Sunenshine, Larry J. Strausbaugh, L. Clifford McDonald, Fred C. Tenover, and the Infectious Diseases Society of America Emerging Infections Network. (2006) Management of Persistent Bacteremia Caused by Methicillin‐Resistant Staphylococcus aureus: A Survey of Infectious Diseases Consultants. Clinical Infectious Diseases 43:5, e42-e45
Online publication date: 1-Sep-2006.
Abstract-Full Text-PDF Version (329 kB)
Dennis L. Stevens. (2006) The Role of Vancomycin in the Treatment Paradigm. Clinical Infectious Diseases 42:s1, S51-S57
Online publication date: 1-Jan-2006.
Abstract-Full Text-PDF Version (389 kB)
Michael J. Rybak. (2006) The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin. Clinical Infectious Diseases 42:s1, S35-S39
Online publication date: 1-Jan-2006.
Abstract-Full Text-PDF Version (202 kB)
Donald P. Levine. (2006) Vancomycin: A History. Clinical Infectious Diseases 42:s1, S5-S12
Online publication date: 1-Jan-2006.
Abstract-Full Text-PDF Version (122 kB)
Ronald N. Jones. (2006) Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep, Bactericidal/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant Strains. Clinical Infectious Diseases 42:s1, S13-S24
Online publication date: 1-Jan-2006.
Abstract-Full Text-PDF Version (185 kB)
G. M. Eliopoulos. (2006) Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. European Journal of Clinical Microbiology & Infectious Diseases 24:12, 826
CrossRef
M. H. Kollef. (2006) Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection. European Journal of Clinical Microbiology & Infectious Diseases 24:12, 794
CrossRef
Abhijit M Bal, Ian M Gould. (2005) Antibiotic resistance in Staphylococcus aureus and its relevance in therapy. Expert Opinion on Pharmacotherapy 6:13, 2257-2269
Online publication date: 1-Nov-2005.
CrossRef
Patrick G. P. Charles, Benjamin P. Howden, Peter B. Ward, Emma J. Bishop, Paul D. R. Johnson, and M. Lindsay Grayson. (2005) Accurate Assessment of Heterogeneous Vancomycin‐Intermediate Staphylococcus aureus Nasal Carriage. Clinical Infectious Diseases 41:7, 1071-1072
Online publication date: 1-Oct-2005.
Citation-Full Text-PDF Version (117 kB)
Fred C Tenover, L Clifford McDonald. (2005) Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Current Opinion in Infectious Diseases 18:4, 300???305
Online publication date: 1-Sep-2005.
CrossRef
Lena M. Napolitano. (2005) Emerging Issues in the Diagnosis and Management of Infections Caused by Multi-Drug-Resistant, Gram-Positive Cocci. Surgical Infections 6:s2, s-5-s-22
Online publication date: 1-Jul-2005.
CrossRef
José M. Eguía, Catherine Liu, Matthew Moore, Elizabeth M. Wrone, Joan Pont, Julie L. Gerberding, and Henry F. Chambers. (2005) Low Colonization Prevalence of Staphylococcus aureus with Reduced Vancomycin Susceptibility among Patients Undergoing Hemodialysis in the San Francisco Bay Area. Clinical Infectious Diseases 40:11, 1617-1624
Online publication date: 1-Jun-2005.
Abstract-Full Text-PDF Version (398 kB)
B. P. Howden, P. B. Ward, P. D. R. Johnson, P. G. P. Charles, M. L. Grayson. (2005) Low-level vancomycin resistance in Staphylococcus aureus?an Australian perspective. European Journal of Clinical Microbiology & Infectious Diseases 24:2, 100-108
Online publication date: 1-Mar-2005.
CrossRef
Stan Deresinski. (2005) Methicillin‐Resistant Staphylococcus aureus: An Evolutionary, Epidemiologic, and Therapeutic Odyssey. Clinical Infectious Diseases 40:4, 562-573
Online publication date: 15-Feb-2005.
Abstract-Full Text-PDF Version (188 kB)
Juan C. Rodr&iacute;guez, Jos&eacute; M. &ETH;lvarez, Isabel Escribano, Gloria Royo. (2005) In vitro Activity of Linezolid against <i>Staphylococcus aureus:</i> A Population Study. Chemotherapy 51:2-3, 86-88
Online publication date: 1-Feb-2005.
CrossRef
Aaron M. Cook, Christian N. Ramsey, Craig A. Martin, Thomas Pittman. (2005) Linezolid for the Treatment of a Heteroresistant <i>Staphylococcus aureus </i>Shunt Infection. Pediatric Neurosurgery 41:2, 102-104
Online publication date: 1-Feb-2005.
CrossRef
S. E. Cosgrove, K. C. Carroll, and T. M. Perl. (2004) Staphylococcus aureus with Reduced Susceptibility to Vancomycin. Clinical Infectious Diseases 39:4, 539-545
Online publication date: 15-Aug-2004.
Abstract-Full Text-PDF Version (183 kB)
Benjamin P. Howden, Peter B. Ward, Patrick G. P. Charles, Tony M. Korman, Andrew Fuller, Philipp du Cros, Elizabeth A. Grabsch, Sally A. Roberts, Jenny Robson, Kerry Read, Narin Bak, James Hurley, Paul D. R. Johnson, Arthur J. Morris, Barrie C. Mayall, and M. Lindsay Grayson. (2004) Treatment Outcomes for Serious Infections Caused by Methicillin‐Resistant Staphylococcus aureus with Reduced Vancomycin Susceptibility. Clinical Infectious Diseases 38:4, 521-528
Online publication date: 15-Feb-2004.
Abstract-Full Text
Back to Top
Close Popup